This Abstract Poster Presentation presented at the FIP World Congress Dublin, Ireland (31 Aug – 5 Sep 2013) deals with the complexites and opportunities presented through compounding for pediatric patients.
Introduction:
The pediatric population is very different from adults and corresponds to a complex and heterogeneous group, from preterm newborn infants to adolescents, with a spectrum of different pathophysiologies associated with growth and development. The dynamic process of maturation profoundly affects the absorption, distribution, metabolism and excretion of medicines and, consequently, the response to therapy. As a result, the pediatric population requires age-appropriate formulations, but the development of such particular medicines represents, almost always, a major challenge to the pharmaceutical industry.